Clinical Trial Update: A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SAGE-547 in severe postpartum depression has completed; results were posted in September 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Depression

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Severe Postpartum Depression | Phase 2 | Status: COMPLETED | Results posted: 2021-09-13